Comparative Pharmacology
Head-to-head clinical analysis: ALA SCALP versus CORDRAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA SCALP versus CORDRAN.
ALA-SCALP vs CORDRAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (PpIX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), PpIX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects.
Topical application of a 5% solution to the scalp twice daily.
Apply a thin layer to the affected skin areas once or twice daily. For CORDRAN Tape, apply tape to affected area once every 12 to 24 hours.
None Documented
None Documented
Not applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
Terminal half-life is approximately 7.5 hours (range 6-10 hours) in adults with normal hepatic function. This supports twined-daily dosing for dermatological indications.
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Primarily hepatic metabolism; metabolites excreted in urine and feces. Renal excretion of unchanged drug is negligible (<5%). Biliary/fecal excretion accounts for ~20% of metabolites.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid